CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Cash Flows From Operating Activities:
Net income (loss)	$ (2,187)	$ 14,128
Adjustments to reconcile net income to net cash used in operating activities:
Depreciation and amortization	7,858	5,536
Realized gain on marketable securities	0	(107)
Gain upon divestiture of assets to Turing Pharmaceuticals	0	(914)
Deferred income tax benefit	(12,286)	(40,021)
Interest income from notes receivable	(1,285)	0
Non-cash interest expense	1,179	1,154
Amortization of premiums on marketable securities	666	0
Amortization of debt discount and deferred financing costs	326	1,010
Lease liability	0	(125)
Legal accrual reversal	(2,967)	0
Bargain purchase gain	0	(49,063)
Share based compensation	14,286	10,567
Derivative financial instruments, warrants, issued, recorded in interest expense	0	1,050
Change in estimated fair value of liability classified warrants	(5,277)	66,171
Change in estimated fair value of contingent consideration	5,485	113
Payments related to change in fair value of contingent consideration	(550)	(90)
Changes in operating assets and liabilities, net of business acquisitions:
Accounts receivable	(4,104)	(3,508)
Inventory	(174)	(640)
Prepaid expenses and other current assets	(1,197)	(420)
Accounts payable and accrued expenses	650	(3,417)
Net cash provided by operating activities	423	1,424
Cash Flows From Investing Activities:
Purchase of fixed assets	(24)	(29)
Cash paid for intangible assets	(4,881)	(2,497)
Proceeds from the sale/maturity of marketable securities	59,874	282
Purchase of marketable securities	(68,517)	0
Cash received upon divestiture of asset	0	3,311
Cash paid upon acquisition, net of cash acquired	(500)	(33,430)
Net cash used in investing activities	(14,048)	(32,363)
Cash Flows From Financing Activities:
Payment of guaranteed minimum royalty	(1,000)	(1,000)
Proceeds from exercise of warrants	90	586
Payment of other liability	(500)	(500)
Proceeds from exercise of stock options	1,572	2,669
Excess benefit related to stock compensation	(236)	0
Proceeds received from issuance of common stock	0	149,454
Financing costs from issuance of common stock	0	(9,500)
Net cash used in (provided by) financing activities	(2,843)	140,481
Effect of exchange rate changes on cash	(182)	0
Net change in cash	(16,650)	109,542
Cash, beginning of year	37,805	18,204
Cash, end of period	21,155	127,746
Manchester
Cash Flows From Financing Activities:
Payment of acquisition-related contingent consideration	(2,125)	(1,228)
Asklepion
Cash Flows From Financing Activities:
Payment of acquisition-related contingent consideration	$ (644)	$ 0